Catalyst Dossier · compiled by CeliA 🧫
Hong Kong Pharma Digital Technology Holdings Ltd (HKPD)
Wholesale-Drugs, Proprietaries & Druggists' Sundries · market cap $9M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-27 (est.)
Phase 2
Pipeline
15
programs
Upcoming events
3
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-27 (est.)Phase 2 · EGCG and Quinine Sulfate Vaginal Suppositoryimp 7/10
- 2026-12-31 (est.)Phase 2 · EI-001imp 7/10
- 2027-01-11Regulatoryimp 4/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EI-001 | Phase 2 | Non-segmental Vitiligo |
| INS018_055 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) |
| ISM3412 | Phase 2 | Locally Advanced/Metastatic Solid Tumors |
| Pegylated Recombinant Human Arginase I | Phase 2 | Neoplasm |
| metformin | Phase 3 | Polycystic Ovary Syndrome |
| AEG35156 antisense IV infusion | Phase 2 | Advanced Hepatocellular Carcinoma |
| prednisolone and mycophenolate mofetil | Phase 3 | Lupus Nephritis |
| PACOX | Phase 2 | Hepatocellular Carcinoma |
| pegylated recombinant human arginase | Phase 2 | Hepatocellular Carcinoma |
| Umbilical Cord Blood Mononuclear Cell | Phase 2 | Spinal Cord Injuries |
| 20-herb formulation | Phase 2 | Irritable Bowel Syndrome |
| EGCG and Quinine Sulfate Vaginal Suppository | Phase 2 | High-risk HPV (Any Strain) |
| Natural killer cell | Phase 2 | Neuroblastoma Recurrent |
| Conventional medication | Phase 3 | Parkinson Disease |
| prednisolone and chlorambucil | Phase 3 | Glomerulonephritis, Membranous |
Price & technical context
3-month
-23.7%
6-month
-55.1%
12-month
-49.9%
52-wk range
$0.61–$2.15
vs 50-day MA
-18.9%
vs 200-day MA
-45.3%
Realized vol
126.0%
Max drawdown
-78.4%
Daily closes through 2026-03-13. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HKPD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.